Pharma and Chemistry Competence Centre of Latvia Ltd. was established within the state support programme “Competence centres”, which was implemented within the framework of the action programme “Entrepreneurship and innovations” sub-activity “Competence centres”, co-financed by the ERDF.

SIA “Pharma and Chemistry Competence Centre of Latvia” was founded by 10 leading Latvian pharmaceutical, chemical and cosmetics companies and scientific institutes: JSC Grindeks, JSC Olainfarm, Latvian Institute of Organic Synthesis, JSC Tenax, JSC Sakret, Silvanols Ltd., PharmIdea Ltd., LabochemLV Ltd., Madara Cosmetics Ltd., Chromsword Baltics Ltd.. More information www.pcccl.lv.

In April 2011, JSC Olainfarm started implementing a range of research projects within the pharmaceutical competence centre Pharma and Chemistry Competence Centre of Latvia Ltd., which, on 5 April 2011, concluded an agreement No. L-KC-11-0001 with the Investment and Development Agency of Latvia on the implementation of the project “Pharma and Chemistry Competence Centre of Latvia”.

Within the project, JSC Olainfarm has implemented the following projects:

1. Development of a technology of synthesis and purification of quinuclidine derivatives. (Completed);
2. A study to improve the technology of synthesising Nitrofuran group preparations. (Completed);
3. Development of production technologies of new finished drug forms. (Individual project). The aim of the study: to develop new drug forms in compliance with principles of Good Manufacturing Practice. The following studies are performed within the project:
   • In vitro and in vivo model studies of the pharmacological profile and efficiency of a hepatoprotective product of plant origin* and the development of a new product form;
   • Development of a production technology of a new Nitrofuran group derivative drug form (with antimicrobial activity);
   • Development of a production technology of a new drug form (with analgesic and anti-inflammatory effect);
   • Production technologies of a new combined drug form, which contains two active pharmaceutical ingredients (with analgesic and anti-inflammatory effect);
   • Two new combined drug forms, which contain, respectively, three and four active pharmaceutical ingredients (to relieve cold and flu symptoms);
   • Study of anti-microbial efficiency.
4. An drug use efficacy and safety study. (Individual project). The aim of the study: to carry out drug efficacy and safety studies according to the principles of Good Manufacturing Practice, Good Clinical Practice, and Good Laboratory Practice. The following studies were performed within the project:
   • Bioequivalence/bioavailability study for amantadine;
   • Bioequivalence/bioavailability study for ipidakrine;
   • Primary planning of drug efficacy and safety studies;
   • Planning and protocol development of drug efficacy and safety studies;
   • Toxicity study;
   • Study of the pharmacological profile of active pharmaceutical ingredients;
   • Bioequivalence/bioavailability study of the drug Adaptol;
   • Bioequivalence/bioavailability study of the drug Fenkarol;
5. Development of a production technology of generic active pharmaceutical ingredients. During the project implementation, it is planned to develop new methods of synthesising and analysing unpatented generic active pharmaceutical ingredients. Additionally, a study and optimisation of synthesis methods performed with the aim of increasing the effectiveness of the production technologies.
6. Development of a technology of synthesising chiral aminobutyric acid derivatives. During the project implementation, a new method of synthesis for the chemical compound group were developed.
7. Study of new crystalline forms of active pharmaceutical ingredients. (Individual project). The aim of the project is to generate new, previously unknown crystalline phases of active pharmaceutical ingredients, which have differing physically-chemical properties. The project was implemented in November 2014.